DeepMed Research

Recombinant Human Granulocyte Colony-stimulating Factor（rhG-CSF）

Generic Name: Recombinant Human Granulocyte Colony-stimulating Factor（rhG-CSF）

Indication: 用于：1.各种原因引起的中性粒细胞减少证，如恶性肿瘤和白血病化疗与放疗引起的中性粒细胞减少、造血干/祖细胞移植后髓系造血功能的受抑及延迟植活鱼移植排斥；

2.周围血造血干/祖细胞移植前的干/祖细胞动员等；

3.骨髓增生异常综合征（MDS）、再生障碍性贫血伴发的中性粒细胞减少，先天性、特发性、周期性中性粒细胞减少症，但远期疗效不肯定；

4.各种严重感染，包括艾滋病及并发的感染；

5.抗艾滋病药物引起的中性粒细胞减少症也可应用。

Clinical Trials

Evaluation of Efficacy and Safety of PD-1 Monoclonal Antibody in Combination With rhG-CSF, IL-2, and CapeOX in Initially Resectable Synchronous Colorectal Liver Metastases

Not yet recruiting

Conditions: Colorectal Cancer

Interventions: Drug: Tislelizumab
Drug: Interleukin-2
Drug: Capecitabine
Drug: Oxaliplatin
Drug: Neupogen

First Posted Date: 2024-07-17

Last Posted Date: 2024-07-17

Lead Sponsor: The First Affiliated Hospital with Nanjing Medical University

Target Recruit Count: 30

Registration Number: NCT06504901

The Impact of Granulocyte Colony Stimulating Factor on Premature Ovarian Insufficiency

Phase 2

Completed

Conditions: Primary Ovarian Insufficiency
Premature Ovarian Failure

Interventions: Drug: Neupogen

First Posted Date: 2023-11-07

Last Posted Date: 2025-05-08

Lead Sponsor: Trio Fertility

Target Recruit Count: 11

Registration Number: NCT06117982

Locations: 🇨🇦
Trio Fertility, Toronto, Ontario, Canada

Clinical Study on PEG-rhG-CSF in Mobilizing Autologous Hematopoietic Stem Cells

Phase 4

Recruiting

Conditions: Lymphoma

Interventions: Drug: PEG-rhG-CSF
Drug: RhG-CSF

First Posted Date: 2023-09-07

Last Posted Date: 2023-09-07

Lead Sponsor: Chongqing University Cancer Hospital

Target Recruit Count: 174

Registration Number: NCT06026995

Locations: 🇨🇳
Chongqing University Cancer Hospital, Chongqing, Chongqing, China

the Efficacy and Safety of PEG-rhG-CSF in Mobilizing Autologous Hematopoietic Stem Cells in Lymphoma

Not Applicable

Not yet recruiting

Conditions: Lymphoma

Interventions: Drug: PEG-rhG-CSF
Drug: RhG-CSF

First Posted Date: 2023-04-28

Last Posted Date: 2023-04-28

Lead Sponsor: Ou Bai, MD/PHD

Target Recruit Count: 144

Registration Number: NCT05834751

Locations: 🇨🇳
The First Bethune Hospital of Jilin University, Changchun, Jilin, China

PEG-rhG-CSF Compared With rhG-CSF in Lymphoma Patients After Autologous Hematopoietic Stem Cell Transplantation

Not Applicable

Conditions: Lymphoma

Interventions: Drug: PEG-rhG-CSF
Drug: rhG-CSF

First Posted Date: 2021-12-14

Last Posted Date: 2021-12-14

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 80

Registration Number: NCT05156554

Study on the Efficacy and Safety of PEG-rhG-CSF in Preventing Neutropenia During Concurrent Chemoradiotherapy of Cervical Cancer

Phase 2

Completed

Conditions: Cervical Cancer

Interventions: Drug: PEG-rhG-CSF
Drug: rhG-CSF

First Posted Date: 2020-09-09

Last Posted Date: 2023-09-06

Lead Sponsor: Chongqing University Cancer Hospital

Target Recruit Count: 60

Registration Number: NCT04542356

Locations: 🇨🇳
Chongqing Cancer Hospital, Chongqing, Chongqing, China

Evaluate the Efficacy and Safety of PEG-rhG-CSF in Patients With Hemophagocytic Syndrome

Not Applicable

Conditions: Hemophagocytic Syndrome

Interventions: Drug: PEG-rhG-CSF
Drug: rhG-CSF

First Posted Date: 2020-08-05

Last Posted Date: 2020-08-05

Lead Sponsor: CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Target Recruit Count: 50

Registration Number: NCT04500886

Locations: 🇨🇳
Beijing Friendship Hospital, Beijing, China

Evaluate the Efficacy and Safety of the Prophylactic Use of PEG-rhG-CSF in Children With Hematological Malignancies

Not Applicable

Conditions: Lymphoma
Leukemia

Interventions: Drug: PEG-rhG-CSF group
Drug: rhG-CSF group

First Posted Date: 2020-08-04

Last Posted Date: 2020-08-04

Lead Sponsor: CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Target Recruit Count: 139

Registration Number: NCT04497701

Locations: 🇨🇳
Children's Hospital of Fudan University, Shanghai, China

Mecapegfilgrastim(PEG-G-CSF) for Prophylaxis of Chemotherapy-induced Neutropenia in Patients With Lymphoma

Phase 2

Conditions: Chemotherapy-induced Neutropenia
Lymphoma

Interventions: Drug: rhG-CSF
Drug: Pegylated rhG-CSF

First Posted Date: 2020-07-07

Last Posted Date: 2022-07-07

Lead Sponsor: The First Hospital of Jilin University

Target Recruit Count: 170

Registration Number: NCT04460508

Locations: 🇨🇳
The First Bethune Hospital of Jilin University, Changchun, Jilin, China

Cost-Effectiveness Study of PEG-rhG-CSF in Prophylactic Treatment of Neutropenia After Chemotherapy in Lymphoma

Phase 4

Conditions: Lymphoma, Non-Hodgkin
Granulocyte Colony-Stimulating Factor
Cost-Benefit Analysis

Interventions: Drug: rhG-CSF
Drug: PEG-rhG-CSF

First Posted Date: 2019-09-10

Last Posted Date: 2019-09-10

Lead Sponsor: Ruijin Hospital

Target Recruit Count: 250

Registration Number: NCT04083079

Locations: 🇨🇳
Ruijin hospital, Shanghai, Shanghai, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy